# A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

> **NCT00249236** · PHASE3 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 291 (actual)

## Conditions studied

- Bipolar Disorder
- Manic Episode

## Interventions

- **DRUG:** Risperidone, oral tablets

## Key facts

- **NCT ID:** NCT00249236
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-03
- **Primary completion:** —
- **Final completion:** 2001-12
- **Target enrollment:** 291 (ACTUAL)
- **Last updated:** 2011-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249236, "A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00249236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*